GI 254023X: Selective ADAM10 Inhibitor for Vascular and Leukemia Research

Executive Summary. GI 254023X is a small-molecule inhibitor with nanomolar potency (IC₅₀ = 5.3 nM) against human ADAM10, offering over 100-fold selectivity versus ADAM17, confirmed in biochemical and cellular assays (APExBIO). It blocks ADAM10-driven substrate shedding, including fractalkine (CX3CL1) and Notch1, modulating cell-cell adhesion and Notch signaling (internal analysis). In vitro, GI 254023X induces apoptosis and suppresses proliferation in Jurkat T-lymphoblastic leukemia cells, with marked effects on Notch1 and MCL-1 expression. In vivo, intraperitoneal administration (200 mg/kg/day, 3 days) in BALB/c mice increases vascular integrity and survival following Staphylococcus aureus α-hemolysin challenge. Recommended for preclinical research, GI 254023X is provided by APExBIO and is not approved for clinical use (Satir et al., 2020).

Biological Rationale

ADAM10 is a member of the disintegrin and metalloproteinase (ADAM) family and acts as a sheddase, cleaving diverse cell surface proteins. Its substrates include fractalkine (CX3CL1), Notch1, and VE-cadherin, all of which are critical in cell-cell communication, immune surveillance, and vascular integrity (Satir et al., 2020). Dysregulated ADAM10 activity has been linked to pathological conditions such as cancer, neurodegeneration, and acute inflammation. Selective inhibition allows researchers to dissect ADAM10's distinct contributions without confounding off-target effects, enabling high-confidence mechanistic studies (Strategic Inhibition of ADAM10—this article provides more focused benchmarking in leukemia and vascular models).

Mechanism of Action of GI 254023X

GI 254023X is a small-molecule inhibitor with the chemical formula C₂₁H₃₃N₃O₄ and a molecular weight of 391.5 g/mol. It binds to the catalytic domain of ADAM10 (EC 3.4.24.81), blocking peptide hydrolysis. The compound exhibits an IC₅₀ of 5.3 nM in ADAM10 enzyme assays and demonstrates >100-fold selectivity over ADAM17, minimizing off-target proteolysis (APExBIO). By inhibiting ADAM10 sheddase activity, it blocks cleavage of surface proteins such as fractalkine and VE-cadherin, and prevents Notch1 activation. This leads to altered cell adhesion, reduced pro-survival signaling, and increased susceptibility to apoptosis in sensitive cells (GI 254023X: Selective ADAM10 Inhibitor—this article extends practical use cases with in vitro/in vivo workflow details).

Evidence & Benchmarks

• GI 254023X inhibits human ADAM10 with an IC₅₀ of 5.3 nM at 25°C, pH 7.5 in Tris buffer (APExBIO).
• It shows >100-fold selectivity for ADAM10 over ADAM17 based on comparative enzymatic assays (APExBIO).
• In Jurkat T-lymphoblastic leukemia cells, GI 254023X (≥1 μM, 24–48 h) induces apoptosis and reduces cell proliferation; Notch1, cleaved Notch1, and MCL-1 expression are suppressed (internal review).
• In HPAECs, pre-treatment with GI 254023X prevents VE-cadherin cleavage and protects against S. aureus α-hemolysin-induced barrier disruption (internal review).
• In BALB/c mice, intraperitoneal dosing at 200 mg/kg/day for 3 days increases vascular integrity and survival post-toxin challenge (APExBIO).
• Distinct from β-secretase (BACE) inhibitors, GI 254023X does not directly affect β-amyloid production or synaptic transmission in neuronal cultures (Satir et al., 2020).

Applications, Limits & Misconceptions

GI 254023X is optimized for research in cell signaling, acute T-lymphoblastic leukemia, and vascular integrity. It is especially valuable for dissecting ADAM10-specific cleavage events and their consequences in disease models. The A4436 kit from APExBIO supports workflows requiring high selectivity and reproducibility, which are not achievable with broad-spectrum metalloprotease inhibitors (GI 254023X: Reliable ADAM10 Inhibition—this article details advanced cell viability use cases, whereas here we focus on translational benchmarks and compound handling).

Common Pitfalls or Misconceptions

• Not a pan-metalloprotease inhibitor: GI 254023X has minimal activity against ADAM17, BACE1, and other metalloproteases at standard concentrations.
• No direct effect on amyloid β generation: Unlike BACE inhibitors, it does not reduce Aβ or impact synaptic transmission in neuronal models (Satir et al., 2020).
• Not approved for clinical use: GI 254023X is for preclinical research only; efficacy and safety in humans are unproven.
• Solubility limitations: The compound is insoluble in water; DMSO or ethanol are required for stock solutions.
• Storage constraints: GI 254023X solutions are unstable at room temperature or upon repeated freeze-thaw cycles; long-term storage is not recommended (APExBIO).

Workflow Integration & Parameters

GI 254023X is supplied as a white solid and should be stored at -20°C. Prepare stock solutions in DMSO (≥42.6 mg/mL) or ethanol (≥46.1 mg/mL); water is unsuitable due to insolubility. For cell-based assays, dilute freshly into culture medium, ensuring final DMSO concentrations are ≤0.1% v/v. Warming or sonication may be used to facilitate dissolution if necessary. For in vivo applications, GI 254023X has been administered intraperitoneally at 200 mg/kg/day for 3 consecutive days in murine models. Avoid prolonged exposure to light or repeated freeze-thaw cycles. Refer to the APExBIO GI 254023X product page for detailed preparation and storage guidelines. For troubleshooting and further assay design, see GI 254023X: Reliable ADAM10 Inhibition (this article updates compound handling and stability considerations).

Conclusion & Outlook

GI 254023X (SKU A4436) is a reference-grade, selective ADAM10 inhibitor offering precise control of sheddase activity in translational research. Its nanomolar potency, robust selectivity, and validated applications in leukemia and vascular models make it a valuable tool for dissecting ADAM10 biology. As highlighted by Satir et al. (2020), distinct ADAM10 and BACE1 inhibition pathways support targeted experimentation in neurobiology and oncology (Satir et al., 2020). For detailed application notes and ordering, visit the APExBIO GI 254023X product page.